title: Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
authors.affiliation: Cardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: C
authors.initials: C
authors.lastname: Pepper
authors.affiliation: Department of Haematology, King's College London, London, UK.
authors.forename: A G S
authors.initials: AG
authors.lastname: Buggins
authors.affiliation: Cardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: C H
authors.initials: CH
authors.lastname: Jones
authors.affiliation: Cardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: E J
authors.initials: EJ
authors.lastname: Walsby
authors.affiliation: Cancer Sciences Unit, CRUK Clinical Centre, University of Southampton, Southampton, UK.
authors.forename: F
authors.initials: F
authors.lastname: Forconi
authors.affiliation: CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, UK.
authors.forename: G
authors.initials: G
authors.lastname: Pratt
authors.affiliation: Department of Haematology, King's College London, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Devereux
authors.affiliation: Cancer Sciences Unit, CRUK Clinical Centre, University of Southampton, Southampton, UK.
authors.forename: F K
authors.initials: FK
authors.lastname: Stevenson
authors.affiliation: Cardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: C
authors.initials: C
authors.lastname: Fegan
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001596:Benzylamines; D054377:Chemokine CXCL12 / Q000235:genetics / Q000378:metabolism; D058534:Class I Phosphatidylinositol 3-Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000080027:Cyclams; D015972:Gene Expression Regulation, Neoplastic; D018740:Genetic Heterogeneity; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics* / Q000378:metabolism; D039441:Integrin alpha4 / Q000235:genetics* / Q000378:metabolism; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009154:Mutation; D000069442:Natalizumab; D010880:Piperidines; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011687:Purines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D016019:Survival Analysis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001596:Benzylamines; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D007143:Immunoglobulin Heavy Chains; D000069442:Natalizumab; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; D019718:Receptors, CXCR4; D039441:Integrin alpha4; C551803:ibrutinib; D058534:Class I Phosphatidylinositol 3-Kinases; C486018:PIK3CD protein, human; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; D000225:Adenine; C088327:plerixafor; C552946:idelalisib